Advatech Corporation is an early stage biotechnology Company. The Company is engaged in the research and development for the commercialization of non-invasive electrical therapies. Nov 14, 2007 09:00 ET Advatech Corp Announces Letter to Shareholders WEST PALM BEACH, FL--(Marketwire - November 14, 2007) - Advatech Corp (PINKSHEETS: ADVA) today issued the following open letter to Shareholders: To Our Shareholders, We would like to thank all of you for your continued support and faith in Advatech Corp's vision for the future as well as offer you an assessment of our progress. We are pleased to announce that the U.S. Patent Office delivered to Advatech an Issued Patent covering the Company's Field Therapy Accelerator ("FTA") device and related technologies. The patent, No.7,288,062, delineates with both Apparatus and Method Claims the unique design and process which involves therapeutic charge transfer in tissue. Advatech's FTA is intended to provide the non-invasive treatment of many forms of trauma using an electric field. To date, various tests of the FTA have demonstrated promising results in areas as varied as rapid wound and burn healing, genetic regulation, and stimulation of cell growth. The promise shown by positive in-vitro and pre-clinical results further indicates a wide variety of future applications. Accordingly, Advatech's breakthrough solution allows powerful non-invasive electrical therapy that has the potential to positively impact healthcare delivery. We continue to investigate a variety of applications for our unique Intellectual Property (IP) involving experiments and trials at: University of Miami Medical School We have completed a number of studies: in-vivo burn wound healing; in-vitro cell culture growth; and on going in-vitro studies on the control of the genetic regulation. A recent discovery by Dr. Li at the UM using our FTA indicates that we can control the activity of some genes in producing the mRNA that controls most cell functions. These results were confirmed by similar research in England. University of Florida We have commenced our first double-blind clinical trial on burn wounds in humans at the University of Florida's Shands Hospital. If the results are consistent with those previously seen in other pre-clinical tests, it could greatly enhance Advatech's ability to commercialize its technologies. Internationally Recognized Research Institute Currently we are engaged in final negotiations with an internationally recognized research institute which has requested the loan and use of our FTA. Their intent is to test the FTA as part of the development for treatment of spinal cord injuries. Agreements are currently being finalized, and we expect that research will begin in the very near future. Angiogenesis We are also exploring the application of the FTA technology to produce angiogenesis. This is the process where new blood vessels infiltrate wounded or damaged tissue. This can be of critical value in a variety of treatments, and is currently of great interest for certain treatments of Myocardial Infarction (MI), commonly known as a heart attack. Our Commercialization Plans Advatech's commercialization strategy is focused on establishing either partnerships or commercial licensing agreements with motivated licensees. These targeted potential licensees or strategic partnerships will offer the necessary development, manufacturing, sales, marketing resources, and capital required to bring Advatech's technology to market. In order to facilitate the assessment, identification, evaluation and search for new potential licensees or strategic partners, we have engaged a leading Business Development Company (BDC). The BDC has extensive experience with medical device and healthcare companies and has provided Advatech an assessment of the Intellectual Property landscape, and derived a list of the prospective licensees. This list will provide the basis of a subsequent commercialization program. Shareholder Value We believe that the current share price does not accurately reflect the value of what we have built. And, the results of our efforts have not yet translated into share value. To date, the shares of ADVA have traded on the OTC market. In order for the shares to be quoted and traded on the Pink Sheets, NASD rules require that a broker/dealer submit information to the NASD gathered pursuant to the Securities and Exchange Act of 1934 (Exchange Act) Rule 15c2-11 before initiating a quotation in the Pink Sheets. The Company intends, as soon as practicable, to begin the process to have its shares quoted and traded on the Pink Sheets. Once trading on Pink Sheets, the Company's common stock may be much more likely to attract additional shareholders and investors with a resulting increase in trading transparency and liquidity while developing a broad base "ownership culture." We have taken the last several years to develop our science and our technology. We value our stakeholders and we are grateful for your continued interest and support. We look forward to sharing our future successes. Sincerely, Board of Directors: Gerald Richman, President, CEO and Chairman Dr. Michael Spiegel, Chief Science Officer and VP of Research and Development Richard Margulies, CFO and Shareholder Relations About Advatech Corp Advatech Corporation is an early stage biotechnology Company. The Company is engaged in the research and development for the commercialization of non-invasive electrical therapies. Safe Harbor Statement This release includes forward-looking Statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions. Contact info: 732-803-8000